FDA Approves Merck’s Injection for Pulmonary Arterial Hypertension
The injection on top of background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone.
The injection on top of background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone.
The outcomes for patients with pulmonary arterial hypertension taking macitentan and tadalafil together in a single pill have been detailed in a new study, which shows significant improvement compared to those taking either drug alone.
Patients with pulmonary hypertension and chronic obstructive pulmonary disease can now be identified by looking at three clinical variables, new research shows.
A new study, presented at the American Association for Thoracic Surgery’s annual meeting, found that patients treated surgically for segmental chronic thromboembolic pulmonary hypertension had positive outcomes.
Read MoreNew research from the American Heart Association revealed beta-blockers were not more likely to cause depression compared to other similar treatments, but the drugs may be linked to unusual dreams, insomnia and sleep disorders.
Read MoreJanssen Pharmaceutical Companies has submitted Uptravi (selexipag) as an injection for intravenous use for the treatment of pulmonary arterial hypertension.
Read MoreResults of a clinical trial show that patients with pulmonary hypertension (PH) have a lower capacity for exercise during hypoxia.
Read MoreHigh dose inhaled nitric oxide resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease.
Read MoreIn certain patients, measurements of pulmonary artery (PA) distensibility are more effective at detecting pulmonary hypertension due to left heart disease than measurements of PA dilatation.
Read MoreAmong 111,356 veterans with pulmonary hypertension, only 1,737 (1.6%) patients received pulmonary rehabilitation.
Read MoreThe patient was treated under an emergency IND filed by a qualified Investigator and approved by the US FDA, according to the manufacturer Vero Biotech.
Read MoreThe implantable Aria CV Pulmonary Hypertension System has received a breakthrough device designation from the FDA, according to the manufacturer Aria CV.
Read MoreNew research found that the cardiac arrhythmia treatment Tikosyn (dofetilide) may be used for treatment of pulmonary arterial hypertension (PAH).
Read MoreFor patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.
Read MorePatients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read More